What is Arocell?

Saving lives with diagnostics.

– We provide knowledge to decision.
Read more about us
– AroCell Group consist of AroCell AB and IDL Biotech.

UBC® Rapid | Bladder Cancer detection

A powerful Doctors-office test (Point-of-Care), for aid in the diagnosis and monitoring of bladder cancer. Read more about UBC® Rapid

TUBEX® TF | Rapid Typhoid Detection

A rapid and sensitive in vitro diagnostic test for detection of acute typhoid fever, a disease caused by Salmonella typhi. Read more about TUBEX® TF

TK 210 ELISA | Cell Proliferation Biomarker

The AroCell TK 210 ELISA kit used for therapy response in subjects with many forms of cancer including several solid tumors. Read more about TK 210 ELISA

Tumor markers licensed to strategic partners

Arocell is constantly building partnerships for establishing projects and developing new products to expand its portfolio. Read More about tumor markers

Press Releases

Example: MFN Loader (Default theme)
19 Feb 2025, 08:00
AroCell AB (publ) Interim Report January 1st to December 31st, 2024
AroCell Interim Report Q4 2024
Regulatory
Interim Report
A word from the CEO” It is with great pleasure that I present this year’s results. The year has been characterized by continuous and strong sales growth. We have increased our sales by over 33% compared to the previous year. This marks the fourth consecutive year of stable sales growth, with a clear
14 Feb 2025, 09:30
New patent approval in China strengthens the AroCell patent portfolio
New patent approval in China strengthens the AroCell patent portfolio
AroCell are glad to announce that the Chinese Patent Office has confirmed the grant of a patent (patent application number: 202080032513.4) to AroCell AB for an invention on the detection and classification of respiratory infections
8 Jan 2025, 13:00
Ellen Dittberner returns as CFO at AroCell on January 13, 2025
Ellen Dittberner returns as CFO at AroCell on January 13, 2025
Regulatory
AroCell AB is pleased to announce that Ellen Dittberner will return to her role as Chief Financial Officer (CFO) on January 13, 2025, after being on parental leave since February 2024. Ellen, who has previously played an important role in AroCell's financial development and strategic success, is now
About us

We provide knowledge to decision.

AroCell is a Swedish diagnostics company with the vision to improve the monitoring of oncological and bacterial diseases. We have a broad product portfolio of IVD tests that deliver high-value clinical information for the detection of diseases.

Read more about us
Investors

We are listed on NASDAQ First North Growth Market.

We want to be the obvious choice within our segment in the markets where we are established. The market for our products is large and we are a smaller player with significant growth potential so far. AroCell is unique for a company of this size.

Read more about investing